ExOne and Fraunhofer IFAM Deepen Partnership on Metal Binder, Materials Development
1.9.2021 15:30:00 EEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, and the Fraunhofer Institute for Manufacturing Technology and Advanced Materials (“Fraunhofer IFAM”), one of the most important independent research institutions in Europe, today announced they are deepening their partnership on binder and materials development projects following the success of CleanFuse™ metal binder.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005493/en/
Parts produced by metal binder jetting before (left) and after (right) sintering. © Fraunhofer IFAM (Photo: Business Wire)
Fraunhofer IFAM’s relationship with ExOne on metal binder jetting development spans more than two decades. They have been working together since about 1998, when ExOne, then part of Extrude Hone, launched the world’s first commercial metal binder jetting system, the RTS-300. In recent years, they have jointly refined and optimized CleanFuse, an ExOne binder based on a development by Fraunhofer IFAM. The result is a clean-burning binder for optimal 3D printing of stainless steels and premium metals.
“When we started developing the first binder version on the Innovent, we soon realized we had a major breakthrough. ExOne was immediately very enthusiastic about our development, because of its exceptional green part strength and clean burnout at low curing temperature. Together with ExOne, we refined the binder, which is now CleanFuse,” says Prof. Frank Petzoldt, Deputy Director of Fraunhofer IFAM since 1999.
Following this success, Fraunhofer IFAM and ExOne have decided to intensify their cooperation and are currently working on a CleanFuse version for processing reactive materials such as aluminum and titanium.
“At ExOne, we truly believe in the power of collaboration – of bringing together a diversity of experts and knowledge – to solve complex problems in the best possible way,” said Rick Lucas, ExOne Chief Technology Officer and VP, New Markets. “Fraunhofer IFAM has been a leading collaboration partner for us – helping to improve our understanding of binders, different types of powders, and how they work together through the entire process chain from printing to final sintering to deliver a quality part.”
Fraunhofer IFAM has a strong foundation in the development and processing of metallic and polymer materials as well as comprehensive knowledge of additive manufacturing technologies – especially for sinter-based processes. The institute’s location in Bremen is fully equipped for sinter-based additive manufacturing and offers all technologies for the printing, depowdering, debinding and sintering of metal parts. The researchers have special know-how around metal powders, binders and their interaction. For research and development in the field of metal binder jetting, they work with a range of ExOne printers starting with the Innovent+ for material and process development. Three printers feature ExOne’s patented Triple Advanced Compaction Technology (ACT) delivering industry- leading green part density. Recently, the institute has put the X1 25Pro® production-speed metal binder jetting system into operation in order to investigate feasibility in context of pilot and pre-series production. Manufacturers interested in metal binder jetting are welcome to schedule a visit to Fraunhofer IFAM Bremen to learn more about the technology and the application possibilities in their fields.
http://www.ifam.fraunhofer.de/de/Presse/Downloads.html
About Fraunhofer IFAM
The Fraunhofer IFAM is one of the most important independent research institutions in Europe for adhesive bonding technology, surfaces, shaping and functional materials. Research and development primarily address industries with special significance for future viability: aviation, automotive, energy technology, medical technology and life sciences, and maritime technologies. At our institute’s five locations – Bremen, Dresden, Stade, Wolfsburg and Braunschweig – as well as at the Test Center for Maritime Technologies on Helgoland – we put our central principles into practice: scientific excellence, a focus on the application of technology, measurable utility at the highest quality for customers. www.ifam.fraunhofer.de
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005493/en/
Contact information
Sarah Webster
Chief Marketing Officer, ExOne
724-516-2336
sarah.webster@exone.com
Randy Eisinger M. A.
Head of Corporate Communications, Fraunhofer IFAM
Phone +49 421 2246-252
randy.eisinger@ifam.fraunhofer.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom